Metabolic syndrome and abdominal fat are associated with inflammation, but not with clinical outcomes, in peritoneal dialysis patients

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Huang, Jenq Wen ^a   Yang, Chung Yi ^a   Wu, Hon Yen ^a,b   Liu, Kao Lang ^a   Su, Chi Ting ^a   Wu, Cho Kai ^a   Lee, Jen Kuang ^b   Chiang, Chih Kang ^a   Cheng, Hui Teng ^a   Lien, Yu Chung ^c   Hung, Kuan Yu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Abdominal fat; Atherogenic indices; Beta blocker; Computed tomography; Metabolic syndrome; Peritoneal dialysis; Renin angiotensin system blocker

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL; AUTACOID; BIOLOGICAL MARKER;

ABDOMINAL FAT; ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIALYSATE; DISEASE ASSOCIATION; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; INFLAMMATION; INTRAABDOMINAL FAT; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NUTRITIONAL PARAMETERS; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SURVIVAL; ADVERSE EFFECTS; AGED; BLOOD; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUTRITIONAL STATUS; OBESITY; OBESITY, ABDOMINAL; PATHOPHYSIOLOGY; RADIOGRAPHY; RISK FACTOR; TIME; TREATMENT OUTCOME;

ABDOMINAL FAT; ADIPOSITY; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; INFLAMMATION; INFLAMMATION MEDIATORS; KAPLAN-MEIER ESTIMATE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUTRITIONAL STATUS; OBESITY, ABDOMINAL; PERITONEAL DIALYSIS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84878668080     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-86     Document Type: Article

References (40)

1. Lear SA, Humphries KH, Kohli S, Frohlich JJ, Birmingham CL, Mancini GB. Visceral adipose tissue, a potential risk factor for carotid atherosclerosis: results of the Multicultural Community Health Assessment Trial (M-CHAT). Stroke 2007, 38(9):2422-2429. 10.1161/STROKEAHA.107.484113, 17673711.
2. Ditomasso D, Carnethon MR, Wright CM, Allison MA. The associations between visceral fat and calcified atherosclerosis are stronger in women than men. Atherosclerosis 2010, 208(2):531-536. 10.1016/j.atherosclerosis.2009.08.015, 19765708.
3. Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B, Tafuri D, Lombardi G, Colao A, Orio F. Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod 2008, 23(1):153-159.
4. Konishi K, Nakano S, Seto H, Tsuda S, Koya D. Carotid atherosclerosis mediated by visceral adiposity and adipocytokines in type 2 diabetic subjects. Diabetes Res Clin Pract 2009, 85(2):171-178. 10.1016/j.diabres.2009.04.021, 19482369.
5. Kishida K, Funahashi T, Matsuzawa Y, Shimomura I. Visceral adiposity as a target for the management of the metabolic syndrome. Ann Med 2012, 44(3):233-241. 10.3109/07853890.2011.564202, 21612331.
6. Mafra D, Guebre-Egziabher F, Fouque D. Body mass index, muscle and fat in chronic kidney disease: questions about survival. Nephrol Dial Transplant 2008, 23(8):2461-2466. 10.1093/ndt/gfn053, 18390566.
7. Huang JW, Lien YC, Wu HY, Yen CJ, Pan CC, Hung TW, Su CT, Chiang CK, Cheng HT, Hung KY. Lean body mass predicts long-term survival in Chinese patients on peritoneal dialysis. PLoS One 2013, 8(1):e54976. 10.1371/journal.pone.0054976, 3555981, 23372806.
8. Odamaki M, Furuya R, Ohkawa S, Yoneyama T, Nishikino M, Hishida A, Kumagai H. Altered abdominal fat distribution and its association with the serum lipid profile in non-diabetic haemodialysis patients. Nephrol Dial Transplant 1999, 14(10):2427-2432. 10.1093/ndt/14.10.2427, 10528668.
9. Kato A, Ishida J, Endo Y, Takita T, Furuhashi M, Maruyama Y, Odamaki M. Association of abdominal visceral adiposity and thigh sarcopenia with changes of arteriosclerosis in haemodialysis patients. Nephrol Dial Transplant 2011, 26(6):1967-1976. 10.1093/ndt/gfq652, 20980356.
10. Miyamoto T, Rashid Qureshi A, Heimburger O, Barany P, Carrero K, Sjoberg B, Lindholm B, Stenvinkel P, Carrero JJ. Inverse relationship between the inflammatory marker pentraxin-3, fat body mass, and abdominal obesity in end-stage renal disease. Clin J Am Soc Nephrol 2011, 6(12):2785-2791. 10.2215/CJN.02320311, 3255358, 22157708.
11. Lee MJ, Shin DH, Kim SJ, Oh HJ, Yoo DE, Kim JK, Park JT, Han SH, Kang SW, Choi KH, et al. Visceral fat thickness is associated with carotid atherosclerosis in peritoneal dialysis patients. Obesity (Silver Spring) 2012, 20(6):1301-1307.
12. Wu HY, Hung KY, Huang TM, Hu FC, Peng YS, Huang JW, Lin SL, Chen YM, Chu TS, Tsai TJ, et al. Safety issues of long-term glucose load in patients on peritoneal dialysis--a 7-year cohort study. PLoS One 2012, 7(1):e30337. 10.1371/journal.pone.0030337, 3264614, 22303440.
13. Wu HY, Hung KY, Huang JW, Chen YM, Tsai TJ, Wu KD. Initial glucose load predicts technique survival in patients on chronic peritoneal dialysis. Am J Nephrol 2008, 28(5):765-771. 10.1159/000128608, 18434715.
14. Wu HY, Hung KY, Hu FC, Chen YM, Chu TS, Huang JW, Wu KD, Tsai TJ. Risk factors for high dialysate glucose use in PD patients--a retrospective 5-year cohort study. Perit Dial Int 2010, 30(4):448-455. 10.3747/pdi.2009.00063, 20228176.
15. Cheng SC, Chu TS, Huang KY, Chen YM, Chang WK, Tsai TJ, Wu KD. Association of hypertriglyceridemia and insulin resistance in uremic patients undergoing CAPD. Perit Dial Int 2001, 21(3):282-289.
16. Chen HY, Kao TW, Huang JW, Chu TS, Wu KD. Correlation of metabolic syndrome with residual renal function, solute transport rate and peritoneal solute clearance in chronic peritoneal dialysis patients. Blood Purif 2008, 26(2):138-144. 10.1159/000113506, 18212496.
17. Li PK, Kwan BC, Ko GT, Chow KM, Leung CB, Szeto CC. Treatment of metabolic syndrome in peritoneal dialysis patients. Perit Dial Int 2009, 29(Suppl 2):S149-S152.
18. Huang JW, Yen CJ, Chiang HW, Hung KY, Tsai TJ, Wu KD. Adiponectin in peritoneal dialysis patients: a comparison with hemodialysis patients and subjects with normal renal function. Am J Kidney Dis 2004, 43(6):1047-1055. 10.1053/j.ajkd.2004.02.017, 15168385.
19. Chujo D, Yagi K, Asano A, Muramoto H, Sakai S, Ohnishi A, Shintaku-Kubota M, Mabuchi H, Yamagishi M, Kobayashi J. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertens Res 2007, 30(12):1205-1210. 10.1291/hypres.30.1205, 18344626.
20. Nakagawa N, Yao N, Hirayama T, Ishida M, Ishida H, Wada A, Fujino T, Saijo Y, Kikuchi K, Hasebe N. Potential impact of renin-angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients. Hypertens Res 2011, 34(5):592-598. 10.1038/hr.2010.282, 21289628.
21. Deedwania P. Hypertension, dyslipidemia, and insulin resistance in patients with diabetes mellitus or the cardiometabolic syndrome: benefits of vasodilating beta-blockers. J Clin Hypertens (Greenwich) 2011, 13(1):52-59.
22. Chan DC, Watts GF. Dyslipidaemia in the metabolic syndrome and type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin Pharmacother 2011, 12(1):13-30. 10.1517/14656566.2010.502529, 20629587.
23. Gotoh H, Gohda T, Tanimoto M, Gotoh Y, Horikoshi S, Tomino Y. Contribution of subcutaneous fat accumulation to insulin resistance and atherosclerosis in haemodialysis patients. Nephrol Dial Transplant 2009, 24(11):3474-3480. 10.1093/ndt/gfp290, 19535435.
24. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001, 34(7):583-588. 10.1016/S0009-9120(01)00263-6, 11738396.
25. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002, 106(25):3143-3421. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
26. Lin CC, Chen CC, Kung PT, Li CI, Yang SY, Liu CS, Lin WY, Lee CC, Li TC, Kardia SL. Joint relationship between renal function and proteinuria on mortality of patients with type 2 diabetes: the taichung diabetes study. Cardiovasc Diabetol 2012, 11:131. 10.1186/1475-2840-11-131, 3515506, 23083001.
27. Kim CS, Choi JS, Park JW, Bae EH, Ma SK, Jeong MH, Kim YJ, Cho MC, Kim CJ, Kim SW, et al. Concomitant renal insufficiency and diabetes mellitus as prognostic factors for acute myocardial infarction. Cardiovasc Diabetol 2011, 10:95. 10.1186/1475-2840-10-95, 3225317, 22035298.
28. Bhardwaj S, Misra A, Misra R, Goel K, Bhatt SP, Rastogi K, Vikram NK, Gulati S. High prevalence of abdominal, intra-abdominal and subcutaneous adiposity and clustering of risk factors among urban Asian Indians in North India. PLoS One 2011, 6(9):e24362. 10.1371/journal.pone.0024362, 3176774, 21949711.
29. Bazanelli AP, Kamimura MA, Manfredi SR, Draibe SA, Cuppari L. Usefulness of waist circumference as a marker of abdominal adiposity in peritoneal dialysis: a cross-sectional and prospective analysis. Nephrol dialy trans off publ European Dialy Trans Assoc European Renal Assoc 2012, 27(2):790-795.
30. Ruan X, Guan Y. Metabolic syndrome and chronic kidney disease. J Diabetes 2009, 1(4):236-245. 10.1111/j.1753-0407.2009.00042.x, 20923524.
31. Guzik TJ, Mangalat D, Korbut R. Adipocytokines - novel link between inflammation and vascular function?. J Physiol Pharmacol 2006, 57(4):505-528.
32. Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001, 12(7):1549-1557.
33. Cordeiro AC, Qureshi AR, Stenvinkel P, Heimburger O, Axelsson J, Barany P, Lindholm B, Carrero JJ. Abdominal fat deposition is associated with increased inflammation, protein-energy wasting and worse outcome in patients undergoing haemodialysis. Nephrol Dial Transplant 2010, 25(2):562-568. 10.1093/ndt/gfp492, 19762603.
34. Lu Q, Cheng LT, Wang T, Wan J, Liao LL, Zeng J, Qin C, Li KJ. Visceral fat, arterial stiffness, and endothelial function in peritoneal dialysis patients. J renal nutri off j Council Renal Nutri Nat Kidney Found 2008, 18(6):495-502.
35. Wu CK, Huang YT, Lin HH, Yang CY, Lien YC, Lee JK, Huang JW, Hung KY. Dissecting the mechanisms of left ventricular diastolic dysfunction and inflammation in peritoneal dialysis patients. PLoS One 2013, 8(5):e62722. 10.1371/journal.pone.0062722, 3652869, 23675418.
36. Saiki A, Ohira M, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Miyashita Y, Shirai K. Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism 2009, 58(5):708-713. 10.1016/j.metabol.2009.01.013, 19375596.
37. McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010, 362(16):1477-1490.
38. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT, Oakes R, Lukas MA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA 2004, 292(18):2227-2236. 10.1001/jama.292.18.2227, 15536109.
39. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis. Am J Kidney Dis 2007, 49(5):581-591. 10.1053/j.ajkd.2007.02.277, 17472839.
40. Perl J, Bargman JM. The importance of residual kidney function for patients on dialysis: a critical review. Am J Kidney Dis 2009, 53(6):1068-1081. 10.1053/j.ajkd.2009.02.012, 19394737.